Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience.
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has become an important therapeutic agent for type 2 diabetes mellitus (T2DM), obesity, and associated cardiometabolic complications. Its prolonged pharmacological activity and availability as subcutaneous and oral formulations have supporte...